5 minute read
Jun. 18, 2022

Pevonedistat: a First-In-Class NEDD8-Activating Enzyme (NAE) Inhibitor

pevonedistat

intravenous NEDD8-activating enzyme inhibitor Ph. III candidate for oncology from HTS and optimization Drug Metab. Dispos., July, 2022 Takeda, Lexington, MA

drughunter.com
Drug Hunter Team

Pevonedistat (Takeda) is a first-in-class intravenous or subcutaneous NEDD8-activating enzyme (NAE) inhibitor being developed for leukemia and advanced solid tumors. NAE is a pivotal regulator of the NEDD8 conjugation pathway which regulates the activity of the Cullin-RING ligases (CRLs), key proteins involved in the [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in